Charmacy Pharmaceutical FY26 H1 net profit rises 3.76% to RMB 22.56 million; revenue climbs 13.6% to RMB 2.45 billion

• Charmacy Pharmaceutical posted revenue of RMB 2.45 billion, up 13.6% year-on-year, for the six months ended June 30, 2026.
• Net profit attributable to shareholders rose 3.76% to RMB 22.56 million; basic and diluted EPS increased to RMB 0.2088.
• Gross profit margin narrowed to 6.51% from 7.46%, due to centralized procurement, medical insurance cost controls, and tighter regulation.
• Finance costs fell 15.93% to RMB 28.32 million, on lower benchmark lending rates and improved capital turnover efficiency.
• Distribution network covered 11,571 customers; commissioned third-party logistics clients rose 24% year-on-year, with related revenue up 41%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charmacy Pharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12308756), on August 31, 2026, and is solely responsible for the information contained therein.